Finance

Lists
Why is ZVRA up 3,55%?
Dive Deeper
ZVRA:NASDAQ
Zevra Therapeutics Inc
11,39 US$
+3,55%
(+0,39) 1D
11,39 US$
0,00% (0,00)
After hours
Closed: 9 ოქტ, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZVRA...
Open
10,95 US$
High
11,46 US$
Low
10,95 US$
Mkt. cap
676,38 მლნ.
Avg. vol.
953,47 ათ.
Volume
730,67 ათ.
P/E ratio
11,89
52-wk high
15,04 US$
52-wk low
8,01 US$
EPS
0,96 US$
Beta
0,98
Shares outstanding
59,38 მლნ.
No. of employees
61
Open
10,95 US$
High
11,46 US$
Low
10,95 US$
Mkt. cap
676,38 მლნ.
Avg. vol.
953,47 ათ.
Volume
730,67 ათ.
P/E ratio
11,89
52-wk high
15,04 US$
52-wk low
8,01 US$
EPS
0,96 US$
Beta
0,98
Shares outstanding
59,38 მლნ.
No. of employees
61
News stories
From web sources and news partners
About Zevra Therapeutics Inc
CEO-
Employees61
Founded2006
Headquarters-
SectorPharmaceutical industry
Websitezevra.com
Analyst ratings
Based on 9 analysts giving stock ratings to ZVRA in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for ZVRA in the last 3 months.
Highest
Current 11,39 US$
35,00 US$ (+207,29%)
Average
25,25 US$ (+121,69%)
Lowest
20,00 US$ (+75,59%)
Analyst
Recommendation
Action
Price target
Projected
Date
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
09/30/2026
Brandon Folkes
H.C. Wainwright
Buy
Maintained
26,00 US$
+128,3%
09/21/2026
Sumant Kulkarni
Canaccord Genuity
Buy
Reiterated
20,00 US$
+75,6%
08/11/2026
Jason McCarthy
Maxim Group
Buy
Maintained
35,00 US$
+207,3%
08/06/2026
Eddie Hickman
Guggenheim
Buy
Maintained
23,00 US$
+101,9%
08/06/2026
Jonathan Aschoff
Roth MKM
Buy
Maintained
21,00 US$
+84,4%
08/06/2026
Kambiz Yazdi
BTIG
Buy
Maintained
24,00 US$
+110,7%
08/05/2026
Jason Butler
Citizens JMP
Buy
Maintained
28,00 US$
+145,8%
08/06/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/06/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
25,00 US$
+119,5%
08/05/2026
Unknown Analyst
Roth MKM
Buy
Maintained
21,00 US$
+84,4%
05/07/2026
Last report
5 აგვ. 2026
Fiscal period
Q2 2026
0,25 US$ / 0,18 US$
+41,51%beat
Revenue / Est. (USD)
39,66 მლნ. / 34,84 მლნ.
+13,85%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
26,06 მლნ.
34,12 მლნ.
36,22 მლნ.
39,66 მლნ.
Cost of goods sold
1,24 მლნ.
1,52 მლნ.
1,90 მლნ.
1,52 მლნ.
Cost of revenue
1,24 მლნ.
1,52 მლნ.
1,90 მლნ.
1,52 მლნ.
Research and development expenses
3,43 მლნ.
2,52 მლნ.
4,39 მლნ.
4,49 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
16,94 მლნ.
20,45 მლნ.
20,78 მლნ.
16,56 მლნ.
Operating expense
20,68 მლნ.
23,29 მლნ.
25,49 მლნ.
21,36 მლნ.
Total operating expenses
21,92 მლნ.
24,81 მლნ.
27,39 მლნ.
22,89 მლნ.
Operating income
4,14 მლნ.
9,32 მლნ.
8,83 მლნ.
16,78 მლნ.
Other non operating income
-5,51 მლნ.
3,56 მლნ.
-6,25 მლნ.
-6,41 მლნ.
EBT including unusual items
-977,00 ათ.
12,67 მლნ.
44,80 მლნ.
12,79 მლნ.
EBT excluding unusual items
-1,10 მლნ.
12,64 მლნ.
4,46 მლნ.
12,93 მლნ.
Income tax expense
-433,00 ათ.
501,00 ათ.
6,91 მლნ.
4,04 მლნ.
Effective tax rate
44,32%
3,96%
15,43%
31,59%
Other operating expenses
-
-
-
-
Net income
-544,00 ათ.
12,16 მლნ.
37,89 მლნ.
8,75 მლნ.
Net profit margin
-2,09%
35,65%
104,61%
22,07%
Earnings per share
-0,01
0,19
0,18
0,25
Interest and investment income
2,31 მლნ.
1,71 მლნ.
3,59 მლნ.
2,56 მლნ.
Interest expense
-2,05 მლნ.
-1,95 მლნ.
-1,71 მლნ.
-
Net interest expenses
262,00 ათ.
-236,00 ათ.
1,88 მლნ.
2,56 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
4,54 მლნ.
9,68 მლნ.
9,20 მლნ.
17,14 მლნ.
Gain or loss from assets sale
-
63,00 ათ.
-43,31 მლნ.
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები